drugset
drugset / Trial / NCT07362017

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

NCT07362017 ↗

Phase 3 Recruiting 300 enrolled Vanda Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Timeline

Start
2026-02-17
Primary completion
2028-08
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponesimod Small molecule — Oral

Indications

psoriasis